Pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus)

September 4, 2019, a pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus) has been held at the Drug Evaluation Center (CDE) of NMPA. CDE representatives include Zhou Ming (Major reviewer), Song Yuanyuan, Xia Lin, Chen Dongmei, Zhang Qian and others. Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd. representatives include Dr. Benjamin Li, Michael Wong, Hande Ping, Li Yujie, Liu Jianfeng, Li Peizhi, Du Yifan.

The release as fetched from its publisher. leespharm.com ↗